Status:
COMPLETED
Origin of CEC in Patients After Allo-HSCT
Lead Sponsor:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Collaborating Sponsors:
Università degli Studi di Brescia
University of Turin, Italy
Conditions:
Graft Versus Host Disease, Acute
Endothelial Dysfunction
Eligibility:
All Genders
18-65 years
Brief Summary
We believe that CEC, besides coming from cells shedding from patient vasculature, could partly belong to donor, originating from the cellular graft.
Detailed Description
In consideration of the fact that the vascular endothelium has been shown to be a target of GvHD in early stage and that the count of CEC represent a marker of endothelial damage, we want to correlate...
Eligibility Criteria
Inclusion
- patients undergoing allo-HSCT for their neoplastic hematologic diseases
- written informed consent
- achievement of hematopoietic recovery from aplasia post-allo-HSCT
- predictable life expectancy \> 6 months
Exclusion
- presence of active malignant hematologic disease at time of allo-HSCT
Key Trial Info
Start Date :
August 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04038827
Start Date
August 27 2019
End Date
April 30 2020
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ASST Spedali Civili di Brescia
Brescia, Italy, 25123